IVVD Stock Risk & Deep Value Analysis
Invivyd Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IVVD Stock
We analyzed Invivyd Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IVVD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IVVD Risk Analysis & Red Flags
What Could Go Wrong
Despite a strong cash position from the recent raise, Invivyd is still burning significant cash from operations (-$173.16M TTM). If PEMGARDA's commercial momentum unexpectedly decelerates or upcoming clinical trial data (Declaration, Liberty) disappoints, the company may face renewed pressure on its cash runway, potentially necessitating further dilutive capital raises before achieving sustainable profitability.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Negative operating cash flow (-$173.16M TTM) indicates continued cash burn from core operations.
- ⚠
Net insider selling activity over the last 90 days, including the CFO, following a positive earnings report.
- ⚠
Despite strong buy ratings from some analysts, the consensus rating is 'Hold', suggesting lingering concerns.
Upcoming Risk Events
- 📅
Disappointing results from Declaration or Liberty trials
- 📅
Slower-than-expected revenue growth for PEMGARDA in Q1/Q2 2026
- 📅
Emergence of a highly effective competitor or significant new COVID-19 variant that bypasses PEMGARDA
When to Reconsider
- 🚪
Exit if quarterly PEMGARDA net product revenue drops below $15M for two consecutive quarters, indicating a loss of commercial traction.
- 🚪
Sell if the Declaration trial top-line data in mid-2026 is negative or shows non-inferiority/safety concerns.
- 🚪
Consider exit if the cash balance drops below $100M without a clear path to profitability or an announced new funding round.
Unlock IVVD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Invivyd Inc (IVVD) Do?
Market Cap
$405.63M
Sector
Healthcare
Industry
Biotechnology
Employees
99
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Visit Invivyd Inc WebsiteInvestment Thesis
Invivyd is strategically positioned to become a leader in proactive immune protection, leveraging its authorized COVID-19 preventative (PEMGARDA) and a rapidly advancing pipeline. Recent strong commercial execution, significant revenue growth, and a bolstered cash position have de-risked immediate financial concerns, establishing a clearer path to sustainable profitability. The company's focus on unmet medical needs in immunocompromised populations, coupled with upcoming clinical catalysts, offers substantial upside potential as it builds a new market category.
Is IVVD Stock Undervalued?
Unlock the full AI analysis for IVVD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IVVD Price Targets & Strategy
12-Month Target
$8.00
Bull Case
$10.00
Bear Case
$0.70
Valuation Basis
Based on analyst consensus and a target of 20x FY26 est. P/S, reflecting accelerated commercialization and pipeline catalysts for a high-growth biotech.
Entry Strategy
Dollar-cost average between current levels ($1.43) and strong support around $1.00-$1.20, especially on any dips following market volatility. Accumulate before mid-2026 clinical data readouts.
Exit Strategy
Take 50% profit at $8.00 (median analyst target), reconsider position at $10.00+ for the remaining. Stop loss at $0.90 if commercial momentum falters or clinical trials disappoint significantly.
Portfolio Allocation
7-15% for aggressive risk tolerance, 3-7% for moderate risk tolerance, considering its small-cap biotech nature.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is IVVD Financially Healthy?
Valuation
P/E Ratio
-3.70
Price/Book
0.73
Price/Sales
26.95
Profitability
Gross Margin
93.34%
Operating Margin
-104.06%
Net Margin
-98.19%
Return on Equity
-67.94%
Revenue Growth
110.60%
EPS
$-0.30
Balance Sheet
Current Ratio
9.14
Debt/Equity
0.02
Total Debt
$2.17M
Cash & Equivalents
$226.69M
Cash Flow
Operating Cash Flow
$173.16M
EBITDA
-$55.56M
Other
Beta (Volatility)
0.61
Does IVVD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is driven by regulatory approval and intellectual property for its lead product. While vulnerable to new competitive monoclonal antibodies or rapid viral evolution, its current market authorization and pipeline expansion into other infectious diseases (measles, RSV) suggest a growing, albeit specific, competitive advantage. Durability depends on continued R&D success and commercial execution.
Moat Erosion Risks
- •Evolution of SARS-CoV-2 variants that significantly diminish PEMGARDA's efficacy, requiring new formulations or treatments.
- •Development and regulatory approval of superior or lower-cost competitive monoclonal antibodies or alternative prophylactic strategies.
- •Expiry of key patents without sufficient pipeline advancement to sustain growth.
IVVD Competitive Moat Analysis
Sign up to see competitive advantages
IVVD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. While growing positive sentiment is emerging around the Q4 beat, the biotech sector and pre-profitability nature typically keeps retail sentiment cautious until sustained profitability is evident.
Institutional Sentiment
Neutral, trending Positive. The consensus is 'Hold', but 3 out of 6 analysts rate it 'Buy', with very high price targets ($8-$10). The significant institutional ownership (70.36%) with recent large stakes from Perceptive Advisors and Eventide indicates growing institutional conviction.
Insider Activity (Form 4)
Net selling activity over the last 90 days. CFO William E. Duke sold 20,964 shares at $1.58 on February 18, 2026, alongside another unnamed insider selling 20,964 shares at the same price.
Options Flow
Normal options activity. No specific unusual options activity or significant skew in put/call ratio indicating institutional positioning was identified in the provided data.
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium
Historical Earnings Pattern
Recent Q4 2025 earnings beat resulted in a modest 2.46% pre-market rise, suggesting cautious optimism despite strong numbers. Prior reactions were likely more volatile given the commercialization challenges.
Key Metrics to Watch
Competitive Position
Top Competitor
No specific peer mentioned in provided data. The company aims to build a new category in prophylactic immune protection.
Market Share Trend
Gaining. PEMGARDA is establishing a market presence with 77% reorder rates and access at 15,000+ GPO sites, indicating strong early commercial traction in a novel category.
Valuation vs Peers
Trading at a high P/S (4.69 trailing, 4.37 forward on FY26 est.) for a pre-profitability biotech, but this reflects the substantial revenue growth (110% YoY FY25) and significant future potential discounted by analysts, as indicated by the 359-485% upside to targets.
Competitive Advantages
- •First-mover advantage with an authorized COVID-19 prevention antibody for immunocompromised individuals.
- •Intangible Assets/IP protection for pemivibart and pipeline candidates.
- •Established commercial infrastructure and payer access for PEMGARDA.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IVVD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (May 7, 2026)
- •Declaration trial top-line data (Mid-2026)
- •Measles program update (H1 2026)
Medium-Term (6-18 months)
- •Liberty trial initiation (Mid-2026)
- •VBY329 IND-readiness (H2 2026)
- •Continued expansion of PEMGARDA market access and reorder rates
Long-Term (18+ months)
- •Potential market leadership in proactive immune protection for vulnerable populations
- •Pipeline expansion into long COVID and RSV antibody programs
- •Leveraging platform for broader infectious disease prevention
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IVVD?
- ✓
Acceleration in PEMGARDA revenue growth, particularly sequential growth rates in upcoming quarters.
- ✓
Positive clinical trial data from Declaration and Liberty trials, validating pipeline potential.
- ✓
Demonstrated progress towards positive free cash flow and reduced net losses quarter-over-quarter.
Bull Case Analysis
See what could go right with Premium
Competing with IVVD
See how Invivyd Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Invivyd Inc IVVD | $405.6M | 7.5 | -3.7 | $53.4M | -98.2% | 110.6% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Invivyd Inc (IVVD)?
As of March 25, 2026, Invivyd Inc has a DVR Score of 7.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Invivyd Inc?
Invivyd Inc's market capitalization is approximately $405.6M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Invivyd Inc use?
IVVD is the ticker symbol for Invivyd Inc. The company trades on the NGM.
What is the risk level for IVVD stock?
Our analysis rates Invivyd Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IVVD?
Invivyd Inc currently has a price-to-earnings (P/E) ratio of -3.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Invivyd Inc's revenue growing?
Invivyd Inc has reported revenue growth of 110.6%. The company is showing strong top-line momentum.
Is IVVD stock profitable?
Invivyd Inc has a profit margin of -98.2%. The company is currently unprofitable.
How often is the IVVD DVR analysis updated?
Our AI-powered analysis of Invivyd Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IVVD (Invivyd Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.